2,480 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,480 shares of the biopharmaceutical company's stock, valued at approximately $229,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Napatree Capital LLC boosted its position in shares of Gilead Sciences by 18.5% in the 4th quarter. Napatree Capital LLC now owns 6,220 shares of the biopharmaceutical company's stock worth $575,000 after buying an additional 971 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Gilead Sciences by 6.1% in the fourth quarter. LPL Financial LLC now owns 1,206,472 shares of the biopharmaceutical company's stock valued at $111,442,000 after purchasing an additional 69,091 shares in the last quarter. Blueprint Investment Partners LLC increased its stake in shares of Gilead Sciences by 59.9% during the 4th quarter. Blueprint Investment Partners LLC now owns 6,771 shares of the biopharmaceutical company's stock worth $625,000 after purchasing an additional 2,537 shares in the last quarter. Mosley Wealth Management raised its position in shares of Gilead Sciences by 5.8% during the 4th quarter. Mosley Wealth Management now owns 5,772 shares of the biopharmaceutical company's stock worth $552,000 after purchasing an additional 319 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Gilead Sciences in the 4th quarter valued at approximately $524,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of brokerages have recently commented on GILD. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last quarter. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Up 1.7 %

Shares of GILD stock traded up $1.89 during mid-day trading on Thursday, reaching $111.16. 6,382,732 shares of the company were exchanged, compared to its average volume of 6,806,689. The company has a market capitalization of $138.43 billion, a P/E ratio of 300.43, a P/E/G ratio of 0.71 and a beta of 0.21. The business's 50 day simple moving average is $105.08 and its 200 day simple moving average is $94.58. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.84%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.